PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34906889-3	2022	Here, we show that the combination of ERK1/2 inhibitor Ulixertinib and MCL-1 inhibitor S63845 is highly synergistic and induces apoptotic cell death in RMS in vitro and in vivo.	S63845	87-93	mitogen-activated protein kinase 3	Homo sapiens	38-44
34906889-6	2022	A genetic silencing approach reveals that BIM, BMF, BAK and BAX are all required for Ulixertinib/S63845-induced apoptosis.	S63845	97-103	BCL2 antagonist/killer 1	Homo sapiens	52-55
34767916-5	2022	In this study, we investigate the Mcl-1 inhibitor S63845 in combination with venetoclax in AML cells.	S63845	50-56	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	34-39
34906889-6	2022	A genetic silencing approach reveals that BIM, BMF, BAK and BAX are all required for Ulixertinib/S63845-induced apoptosis.	S63845	97-103	BCL2 associated X, apoptosis regulator	Homo sapiens	60-63
34906889-7	2022	Overexpression of BCL-2 rescues cell death triggered by Ulixertinib/S63845 co-treatment, confirming that combined inhibition of ERK1/2 and MCL-1 effectively induces cell death of RMS cells via the intrinsic mitochondrial apoptotic pathway.	S63845	68-74	BCL2 apoptosis regulator	Homo sapiens	18-23
34564697-0	2021	Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.	S63845	65-71	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	50-54
34728569-2	2022	S63845 is a highly specific inhibitor of MCL1.	S63845	0-6	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	41-45
34707185-7	2021	Indeed, the Mcl-1-specific inhibitor S63845 restored apoptosis by disrupting the interaction of Mcl-1 with Bim and Bak and significantly increased AraC toxicity in CD157-high but not in CD157-low AML cells.	S63845	37-43	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	12-17
34707185-7	2021	Indeed, the Mcl-1-specific inhibitor S63845 restored apoptosis by disrupting the interaction of Mcl-1 with Bim and Bak and significantly increased AraC toxicity in CD157-high but not in CD157-low AML cells.	S63845	37-43	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	96-101
34707185-7	2021	Indeed, the Mcl-1-specific inhibitor S63845 restored apoptosis by disrupting the interaction of Mcl-1 with Bim and Bak and significantly increased AraC toxicity in CD157-high but not in CD157-low AML cells.	S63845	37-43	BCL2 like 11	Homo sapiens	107-110
34707185-7	2021	Indeed, the Mcl-1-specific inhibitor S63845 restored apoptosis by disrupting the interaction of Mcl-1 with Bim and Bak and significantly increased AraC toxicity in CD157-high but not in CD157-low AML cells.	S63845	37-43	BCL2 antagonist/killer 1	Homo sapiens	115-118
34707185-7	2021	Indeed, the Mcl-1-specific inhibitor S63845 restored apoptosis by disrupting the interaction of Mcl-1 with Bim and Bak and significantly increased AraC toxicity in CD157-high but not in CD157-low AML cells.	S63845	37-43	bone marrow stromal cell antigen 1	Homo sapiens	164-169
34675185-8	2021	FASN inhibition, however, fails to sensitize breast cancer cells to MCL-1- and BCL-XL-selective inhibitors such as S63845 and A1331852.	S63845	115-121	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	68-73
34675185-8	2021	FASN inhibition, however, fails to sensitize breast cancer cells to MCL-1- and BCL-XL-selective inhibitors such as S63845 and A1331852.	S63845	115-121	BCL2 like 1	Homo sapiens	79-85
34632715-6	2022	In BCL2-negative lymphoma cells, instead, killing by IACS-010759 was potentiated by the Mcl-1 inhibitor S63845.	S63845	104-110	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	88-93
34360855-0	2021	Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.	S63845	93-99	fms related receptor tyrosine kinase 3	Homo sapiens	120-124
34568318-8	2021	To overcome this adaptation, we employed the BH3 mimetic S63845, a specific MCL-1 inhibitor, and evaluated its sequential addition to both kinase inhibitors to overcome resistance.	S63845	57-63	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	76-81
34385422-4	2021	Cells bearing BAK/MCL1 complexes were more sensitive to paclitaxel and the MCL1 antagonist S63845.	S63845	91-97	BCL2 antagonist/killer 1	Homo sapiens	14-17
34385422-4	2021	Cells bearing BAK/MCL1 complexes were more sensitive to paclitaxel and the MCL1 antagonist S63845.	S63845	91-97	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	18-22
34385422-4	2021	Cells bearing BAK/MCL1 complexes were more sensitive to paclitaxel and the MCL1 antagonist S63845.	S63845	91-97	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	75-79
34385422-7	2021	Further studies indicated that cells with preformed BAK/MCL1 complexes were sensitive to the paclitaxel/S63845 combination, while cells without BAK/MCL1 complexes were not.	S63845	104-110	BCL2 antagonist/killer 1	Homo sapiens	52-55
34385422-7	2021	Further studies indicated that cells with preformed BAK/MCL1 complexes were sensitive to the paclitaxel/S63845 combination, while cells without BAK/MCL1 complexes were not.	S63845	104-110	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	56-60
34331013-5	2021	Because addition of the BCL2 inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug combination composed of sirolimus, venetoclax, and the MCL1 inhibitor S63845.	S63845	195-201	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	180-184
34088831-6	2021	Second, the MCL-1 inhibitor S63845 sensitizes MYCN-amplified NB through neutralization of MCL-1, inducing synergistic cell killing when combined with venetoclax.	S63845	28-34	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	46-50
34360855-0	2021	Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.	S63845	93-99	tet methylcytosine dioxygenase 2	Homo sapiens	136-140
34360855-7	2021	Synergistic effects on cell viability were detected in both FLT3-mutated and FLT3-wild-type AML cells treated with AC-4-130 in combination with the MCL1 inhibitor S63845.	S63845	163-169	fms related receptor tyrosine kinase 3	Homo sapiens	60-64
34360855-7	2021	Synergistic effects on cell viability were detected in both FLT3-mutated and FLT3-wild-type AML cells treated with AC-4-130 in combination with the MCL1 inhibitor S63845.	S63845	163-169	fms related receptor tyrosine kinase 3	Homo sapiens	77-81
34360855-11	2021	The combination of the STAT5-inhibitor AC-4-130 and the MCL1 inhibitor S63845 may be an effective treatment targeting FLT3-mutated or TET2-mutated AML.	S63845	71-77	fms related receptor tyrosine kinase 3	Homo sapiens	118-122
34360855-11	2021	The combination of the STAT5-inhibitor AC-4-130 and the MCL1 inhibitor S63845 may be an effective treatment targeting FLT3-mutated or TET2-mutated AML.	S63845	71-77	tet methylcytosine dioxygenase 2	Homo sapiens	134-138
34103421-7	2021	The combination of a NAMPT inhibitor (FK866) and an MCL-1 antagonist (S63845) reduced tumor growth in a TNBC patient-derived xenograft model in vivo.	S63845	70-76	nicotinamide phosphoribosyltransferase	Homo sapiens	21-26
34103421-7	2021	The combination of a NAMPT inhibitor (FK866) and an MCL-1 antagonist (S63845) reduced tumor growth in a TNBC patient-derived xenograft model in vivo.	S63845	70-76	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	52-57
35393436-5	2022	Indeed, we found that the MCL-1 inhibitor S63845 synergistically enhanced trametinib cytotoxicity in rhabdomyosarcoma cells in vitro and in vivo.	S63845	42-48	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	26-31
35449130-6	2022	While treatment with the Bcl-2 inhibitor Navitoclax results in the reduction of metastases in tumor bearing mice, treatment with the Mcl-1 inhibitor S63845 leads to complete elimination of senescent tumor cells and metastases.	S63845	149-155	B cell leukemia/lymphoma 2	Mus musculus	25-30
35449130-6	2022	While treatment with the Bcl-2 inhibitor Navitoclax results in the reduction of metastases in tumor bearing mice, treatment with the Mcl-1 inhibitor S63845 leads to complete elimination of senescent tumor cells and metastases.	S63845	149-155	myeloid cell leukemia sequence 1	Mus musculus	133-138
35201512-10	2022	Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival.	S63845	64-70	BCL2 apoptosis regulator	Homo sapiens	27-32
35138523-5	2022	METHODS AND RESULTS: Mononuclear cells from patients with Pre-B ALL and BCP-ALL cell lines were treated with S63845 in presence or absence of doxorubicin, induction of apoptosis was evaluated using Annexin-V/PI staining kit.	S63845	109-115	annexin A5	Homo sapiens	198-207
35201512-10	2022	Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival.	S63845	64-70	BCL2 like 1	Homo sapiens	225-231
35201512-10	2022	Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival.	S63845	64-70	BCL2 like 1	Homo sapiens	283-289
35201512-10	2022	Co-inhibition of MCL-1 and BCL-2 with MCL-1 selective inhibitor S63845 and BCL-2 selective inhibitor ABT-199 inhibited NPC cell proliferation but the effect on cell viability was more profound with co-inhibition of MCL-1 and BCL-XL with S63845 and A-1331852, implying that MCL-1 and BCL-XL are crucial for NPC cell survival.	S63845	237-243	BCL2 apoptosis regulator	Homo sapiens	27-32
32885857-10	2020	Both miR-193b and S63845 resulted in significant enhancement of TRAIL-induced apoptosis, associated with decreased cell viability.	S63845	18-24	TNF superfamily member 10	Homo sapiens	64-69
33540760-5	2021	RESULTS: AML cell lines were variably susceptible to PTC596 and to combination treatments with PTC596 and MCL1 inhibitor S63845, MEK inhibitor trametinib, or TP53 activator APR-246, independent of TP53 mutational status.	S63845	121-127	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	106-110
33540760-6	2021	Susceptibility of patient samples for PTC596 in combination with S63845 or trametinib was significant for the majority of adverse risk primary and secondary AML with minimal efficacy in favorable risk AML, and correlated significantly with CD34 positivity of the samples.	S63845	65-71	CD34 molecule	Homo sapiens	240-244
33540760-8	2021	CONCLUSIONS: The combination of PTC596 and S63845 may be an effective treatment in CD34+ adverse risk AML with elevated MN1 gene expression and MCL1 protein levels, while PTC596 and trametinib may be more effective in CD34+ adverse risk AML with elevated BMI1 gene expression and MEK protein levels.	S63845	43-49	CD34 molecule	Homo sapiens	83-87
33540760-8	2021	CONCLUSIONS: The combination of PTC596 and S63845 may be an effective treatment in CD34+ adverse risk AML with elevated MN1 gene expression and MCL1 protein levels, while PTC596 and trametinib may be more effective in CD34+ adverse risk AML with elevated BMI1 gene expression and MEK protein levels.	S63845	43-49	MN1 proto-oncogene, transcriptional regulator	Homo sapiens	120-123
33540760-8	2021	CONCLUSIONS: The combination of PTC596 and S63845 may be an effective treatment in CD34+ adverse risk AML with elevated MN1 gene expression and MCL1 protein levels, while PTC596 and trametinib may be more effective in CD34+ adverse risk AML with elevated BMI1 gene expression and MEK protein levels.	S63845	43-49	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	144-148
32659848-3	2020	We thus tested the anti-leukemic activity of S63845, a specific MCL-1 inhibitor.	S63845	45-51	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	64-69
33690800-3	2021	BH3 profiling demonstrates their addiction to MCL1 (myeloid cell leukemia-1), which can be targeted with the small molecule inhibitor S63845.	S63845	134-140	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	52-75
33564073-9	2021	Moreover, combination of ETC-168 and MCL1 inhibitor S63845 exerts a synergistic antiproliferative activity against STS cells.	S63845	52-58	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	37-41
32128842-7	2020	Incubation with the MCL1 inhibitor S63845, a pro-apoptotic BH3-mimetic therapy significantly decreased DKO and Mdr2-/- ERC viability compared to WT.	S63845	35-41	myeloid cell leukemia sequence 1	Mus musculus	20-24
32990536-6	2021	In this review, we summarize the recent literature on small molecule and peptide inhibitors of Mcl-1, which are divided into different types including: peptide inhibitors, gossypol derivatives, marinopyrrole derivatives, S1 derivatives, indole derivatives, quinoline derivatives, S63845, AZD5991, AMG176, etc.	S63845	280-286	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	95-100
32128842-7	2020	Incubation with the MCL1 inhibitor S63845, a pro-apoptotic BH3-mimetic therapy significantly decreased DKO and Mdr2-/- ERC viability compared to WT.	S63845	35-41	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	111-115
32066201-0	2020	Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.	S63845	27-33	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	38-42
32801295-6	2020	We validated this strategy in vivo using a RMS patient-derived xenograft model and observed a reduction in tumor growth with a tendency to stabilization with the sequential combination of vincristine and the MCL-1 inhibitor S63845.	S63845	224-230	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	208-213
32801295-7	2020	We identified the molecular mechanism by which RMS cells acquire resistance to vincristine: an enhanced binding of BID and BAK to MCL-1 after drug exposure, which is suppressed by subsequently adding S63845.	S63845	200-206	BH3 interacting domain death agonist	Homo sapiens	115-118
32801295-7	2020	We identified the molecular mechanism by which RMS cells acquire resistance to vincristine: an enhanced binding of BID and BAK to MCL-1 after drug exposure, which is suppressed by subsequently adding S63845.	S63845	200-206	BCL2 antagonist/killer 1	Homo sapiens	123-126
32801295-7	2020	We identified the molecular mechanism by which RMS cells acquire resistance to vincristine: an enhanced binding of BID and BAK to MCL-1 after drug exposure, which is suppressed by subsequently adding S63845.	S63845	200-206	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	130-135
32724460-7	2020	RESULTS: We found that highly potent and specific Mcl-1 inhibitors such as S63845 overcame regorafenib resistance by restoring apoptosis in multiple regorafenib-resistant CRC models.	S63845	75-81	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	50-55
32513939-0	2020	MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.	S63845	16-22	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-4
32346617-11	2020	Co-inhibition of BCL-XL and MCL-1 with A1331852 and S63845 significantly inhibited cell proliferation of all four cell lines.	S63845	52-58	BCL2 like 1	Homo sapiens	17-23
32346617-11	2020	Co-inhibition of BCL-XL and MCL-1 with A1331852 and S63845 significantly inhibited cell proliferation of all four cell lines.	S63845	52-58	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	28-33
31856269-3	2019	In this study, we investigated whether sensitivity to the novel MCL-1 inhibitor S63845 could be predicted using cytogenetics, focusing on amplification of 1q21, the chromosomal region that contains the MCL1 locus.	S63845	80-86	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	64-69
31078737-6	2019	In contrast, the Mcl-1 inhibitor S63845 potently targeted basal-like, but not stem-like cells, highlighting dependency on distinct sentinel Bcl-2 family members.	S63845	33-39	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	17-22
31078737-6	2019	In contrast, the Mcl-1 inhibitor S63845 potently targeted basal-like, but not stem-like cells, highlighting dependency on distinct sentinel Bcl-2 family members.	S63845	33-39	BCL2 apoptosis regulator	Homo sapiens	140-145
31004002-9	2019	Consequently, we tested an experimental treatment strategy based on cotargeting BCL2 with venetoclax and MCL1 with a highly specific small-molecule MCL1 inhibitor S63845.	S63845	163-169	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	148-152
30008477-0	2019	The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.	S63845	28-34	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	4-8
30214012-4	2019	We now report the pre-clinical anti-leukemic efficacy of a novel BCL-2 inhibitor S55746, which demonstrates synergistic pro-apoptotic activity in combination with the MCL1 inhibitor S63845.	S63845	182-188	BCL2 apoptosis regulator	Homo sapiens	65-70
30214012-4	2019	We now report the pre-clinical anti-leukemic efficacy of a novel BCL-2 inhibitor S55746, which demonstrates synergistic pro-apoptotic activity in combination with the MCL1 inhibitor S63845.	S63845	182-188	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	167-171
28768804-4	2017	We tested the MCL-1 inhibitor S63845 in breast cancer cell lines and patient-derived xenografts with high expression of MCL-1.	S63845	30-36	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	120-125
30017199-11	2018	Indeed, the newly developed Mcl-1 inhibitor S63845 in combination with ABT-199 had a synergistic effect on NPC cell apoptosis.	S63845	44-50	myeloid cell leukemia sequence 1	Mus musculus	28-33
28768804-4	2017	We tested the MCL-1 inhibitor S63845 in breast cancer cell lines and patient-derived xenografts with high expression of MCL-1.	S63845	30-36	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	14-19
27760111-0	2016	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.	S63845	19-25	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	4-8